{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:20:54Z","timestamp":1744165254765},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.8846-17","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T22:12:08Z","timestamp":1504649528000},"page":"2603-2609","source":"Crossref","is-referenced-by-count":5,"title":["Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction"],"prefix":"10.2169","volume":"56","author":[{"given":"Shigeo","family":"Godo","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan"},{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoo","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"},{"name":"Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Kushimoto","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tohoku University Hospital, Japan"},{"name":"Division of Emergency and Critical Care Medicine, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Chiha M, Samarasinghe S, Kabaker AS. Thyroid storm: an updated review. J Intensive Care Med 30: 131-140, 2015."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 388: 906-918, 2016.","DOI":"10.1016\/S0140-6736(16)00278-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tagami T, Yambe Y, Tanaka, et al. Short-term effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves' disease. Intern Med 51: 2285-2290, 2012.","DOI":"10.2169\/internalmedicine.51.7302"},{"key":"4","unstructured":"4. Satoh T, Isozaki O, Suzuki A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (first edition). Endocr J 63: 1025-1064, 2016."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lee HY, Baek SH. Optimal use of beta-blockers for congestive heart failure. Circ J 80: 565-571, 2016.","DOI":"10.1253\/circj.CJ-16-0101"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26: 1343-1421, 2016.","DOI":"10.1089\/thy.2016.0229"},{"key":"7","unstructured":"7. Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-Land Study). Circ J 77: 908-916, 2013."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ogiso S, Inamoto S, Hata H, Yamaguchi T, Otani T, Koizumi K. Successful treatment of gastric perforation with thyrotoxic crisis. Am J Emerg Med 26: 1065 e3-1065 e4, 2008.","DOI":"10.1016\/j.ajem.2008.03.005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yamashita Y, Iguchi M, Nakatani R, et al. Thyroid storm with heart failure treated with a short-acting beta-adrenoreceptor blocker, landiolol hydrochloride. Intern Med 54: 1633-1637, 2015.","DOI":"10.2169\/internalmedicine.54.3138"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 22: 263-277, 1993.","DOI":"10.1016\/S0889-8529(18)30165-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 327: 94-98, 1992.","DOI":"10.1056\/NEJM199207093270206"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Rawles JM. What is meant by a "controlled" ventricular rate in atrial fibrillation? Br Heart J 63: 157-161, 1990.","DOI":"10.1136\/hrt.63.3.157"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev 4: 378-388, 1983.","DOI":"10.1210\/edrv-4-4-378"},{"key":"14","unstructured":"14. Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T. Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. J Clin Hypertens 15: 806-814, 2013."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura K, Inokuchi R, Hiruma T, Tokunaga K, Doi K, Nakajima S. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J Anesth 30: 891-894, 2016.","DOI":"10.1007\/s00540-016-2199-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hara T, Yagi S, Akaike M, Sata M. Transdermal patch of bisoprolol for the treatment of hypertension complicated with aortic dissection. Int J Cardiol 198: 220-221, 2015.","DOI":"10.1016\/j.ijcard.2015.06.112"},{"key":"17","unstructured":"17. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 123: 1144-1150, 2011."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 78: 1997-2021, 2014.","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"19","unstructured":"19. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37: 2893-2962, 2016."},{"key":"20","unstructured":"20. David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 44: 1378-1382, 1979."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Dalan R, Leow MK. Cardiovascular collapse associated with beta blockade in thyroid storm. Exp Clin Endocrinol Diabetes 115: 392-396, 2007.","DOI":"10.1055\/s-2007-971065"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull 40: 1462-1469, 1992.","DOI":"10.1248\/cpb.40.1462"},{"key":"23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000355312","volume":"127","author":"S Kobayashi","year":"2014","unstructured":"23. Kobayashi S, Murakami W, Myoren T, et al. A low-dose beta1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology 127: 105-113, 2014.","journal-title":"Cardiology","ISSN":"http:\/\/id.crossref.org\/issn\/0008-6312","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/19\/56_8846-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T04:51:27Z","timestamp":1570078287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/19\/56_8846-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8846-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}